Vivek Subbiah: Celebrating the relentless pursuit of innovation in cancer research
Vivek Subbiah shared a post on X:
“On World Cancer Research Day week, we celebrate the relentless pursuit of innovation in cancer research. Every breakthrough brings us closer to a cure.
Let’s continue to support the science that saves lives. Together, we can conquer cancer.
Precision Oncology Hope For A Cure Pic: Times Square, NY, are our incredible multi-stakeholder colleagues from around the globe, all dedicated to the relentless fight against cancer.”
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023